PNA Probe PCR Assay for EGFR Mutation Detection in Blood
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting EGFR mutations in lung cancer patients are limited, especially in early stages and non-invasive neoplasms, as they require the presence of metastatic circulating cancer cells and are not effective in peripheral blood samples, which are easily accessible but often ignored.
Innovation Solution
A PCR-based assay using a Protein-Nucleic Acid (PNA) probe for amplifying and detecting EGFR mutations in plasma/serum samples, enhancing sensitivity and allowing for the rapid identification of patients likely to respond to specific EGFR inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If direct sequencing or single-strand conformation polymorphism analysis is used for EGFR mutation detection, then the method is simple to perform, but the sensitivity is insufficient to detect small numbers of mutant molecules in blood samples
Solution Approach 1:
The assay is divided into distinct functional modules: PCR amplification module, PNA probe hybridization module, and detection module. This segmentation allows each component to be optimized independently for sensitivity while maintaining overall assay manageability.
Solution Approach 2:
PNA probes serve as intermediaries that specifically bind to mutant EGFR sequences, enabling highly sensitive detection of mutant molecules amidst background wild-type DNA in blood samples without requiring complex sample preparation.
2Measurement precision
If nucleic acid amplification methods are used to detect mutant molecules in blood samples, then the detection sensitivity improves, but the requirement for metastatic circulating cancer cells limits applicability to early stage and non-invasive neoplasms
Solution Approach 1:
The PNA probe-based PCR assay is designed to detect EGFR mutations from any source of DNA containing the mutation, whether from circulating tumor cells, cell-free tumor DNA, or other sources, making it universally applicable across early-stage cancer, non-invasive neoplasms, and advanced cancer.
Solution Approach 2:
The assay parameters are optimized to detect extremely low levels of mutant DNA (as low as 1 mutant molecule among 10,000 wild-type molecules), enabling detection in blood samples from early-stage cancer patients who have minimal circulating tumor DNA.
3Ease of operation
If serum or plasma fraction of blood is ignored or discarded prior to analysis, then the analysis process is simplified, but the opportunity to detect EGFR mutations in easily accessible peripheral blood samples is lost
Solution Approach 1:
The invention extracts and utilizes the previously discarded serum or plasma fraction of blood samples, isolating cell-free DNA from this fraction to detect EGFR mutations. This extracts valuable diagnostic information from material that was previously wasted.
Solution Approach 2:
The PNA probe technique creates a specific copy of the mutant sequence through selective hybridization and amplification, allowing detection of rare mutant molecules in the complex background of serum/plasma DNA without requiring isolation of circulating tumor cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a robust and accessible approach for detecting EGFR mutations in peripheral blood, improving the identification of lung cancer patients who may benefit from EGFR inhibitors, even in cases where direct tissue analysis is difficult or impossible.
Implementation Method 1
amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe
Data Source
AI summary
The present invention refers to the detection of EGFR mutations in a blood (serum/plasma) sample from a subject. The method comprises: (i) obtaining the DNA from said sample; (ii) amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe; 10 and (iii) detecting said mutation.